Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $216.80 and traded as high as $234.79. Jazz Pharmaceuticals shares last traded at $229.74, with a volume of 1,680,855 shares.
Trending Headlines about Jazz Pharmaceuticals
Here are the key news stories impacting Jazz Pharmaceuticals this week:
- Positive Sentiment: Better-than-expected results and higher guidance: Third-quarter revenue was $1.24 billion, up 10.4% year over year and above the $1.21 billion consensus. The reported $3.88-per-share loss was narrower than analysts expected. Jazz raised its 2026 revenue forecast to about $4.78 billion–$4.85 billion, above the prior consensus near $4.7 billion. Jazz Pharmaceuticals third-quarter results
- Positive Sentiment: $500 million share buyback: The repurchase authorization may support shareholder returns and signals management’s willingness to return capital. Jazz Pharmaceuticals announces share buyback
- Positive Sentiment: Analyst target increases: JPMorgan, Morgan Stanley, RBC and Barclays raised their price targets and maintained positive ratings, adding to the favorable reaction to results and guidance. JPMorgan analyst recommendations Morgan Stanley analyst recommendations
- Neutral Sentiment: Pipeline updates ahead: Jazz plans to present neuro-oncology research, including progress in its Phase 3 ACTION trial, at a November meeting. Any investment impact may depend on the data and subsequent development progress. Jazz neuro-oncology research at SNO 2026
- Negative Sentiment: Loss versus prior-year earnings: The quarterly per-share loss contrasts with earnings of $8.13 a year earlier, and coverage noted an Actio-related charge. This tempers the otherwise strong revenue and outlook news. Jazz reports quarterly loss and beats revenue estimates
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on JAZZ. Wall Street Zen downgraded Jazz Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, October 3rd. Wells Fargo & Company increased their price target on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 4th. Robert W. Baird raised their price target on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the company an "outperform" rating in a report on Tuesday, August 4th. UBS Group lifted their price objective on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a "buy" rating in a research note on Friday, September 11th. Finally, Truist Financial upped their price objective on shares of Jazz Pharmaceuticals from $281.00 to $286.00 and gave the stock a "buy" rating in a report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $293.45.
View Our Latest Stock Report on Jazz Pharmaceuticals
Jazz Pharmaceuticals Price Performance
The stock has a market capitalization of $14.91 billion, a price-to-earnings ratio of 78.14, a P/E/G ratio of 0.43 and a beta of 0.38. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. The business has a 50-day simple moving average of $230.67 and a two-hundred day simple moving average of $216.80.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.04) by $0.16. Jazz Pharmaceuticals had a return on equity of 16.55% and a net margin of 4.37%. The company had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $1.21 billion. During the same period last year, the firm earned $8.13 EPS. The firm's revenue for the quarter was up 10.4% on a year-over-year basis. As a group, research analysts predict that Jazz Pharmaceuticals PLC will post 10.87 earnings per share for the current fiscal year.
Insider Transactions at Jazz Pharmaceuticals
In related news, Director Bruce Cozadd sold 6,000 shares of the firm's stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $230.33, for a total transaction of $1,381,980.00. Following the completion of the transaction, the director owned 345,875 shares of the company's stock, valued at $79,665,388.75. This trade represents a 1.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena Patil sold 1,200 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $240.94, for a total value of $289,128.00. Following the transaction, the executive vice president directly owned 47,671 shares in the company, valued at approximately $11,485,850.74. The trade was a 2.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 94,121 shares of company stock worth $23,337,922. Corporate insiders own 4.10% of the company's stock.
Hedge Funds Weigh In On Jazz Pharmaceuticals
Several hedge funds have recently made changes to their positions in JAZZ. Point Nemo Capital LLC acquired a new stake in Jazz Pharmaceuticals during the third quarter valued at approximately $1,345,000. Ethic Inc. bought a new stake in Jazz Pharmaceuticals during the third quarter worth approximately $1,265,000. Pictet Asset Management Holding SA grew its position in Jazz Pharmaceuticals by 1.0% in the third quarter. Pictet Asset Management Holding SA now owns 149,115 shares of the specialty pharmaceutical company's stock worth $34,640,000 after buying an additional 1,516 shares during the last quarter. Pegasus Asset Management Inc. acquired a new position in Jazz Pharmaceuticals in the third quarter worth approximately $3,664,000. Finally, AlphaCentric Advisors LLC grew its position in Jazz Pharmaceuticals by 29.8% in the third quarter. AlphaCentric Advisors LLC now owns 4,688 shares of the specialty pharmaceutical company's stock worth $1,085,000 after buying an additional 1,075 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.
About Jazz Pharmaceuticals
(
Get Free Report)
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.
Jazz's sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Jazz Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.
While Jazz Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.